TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT04848064

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing Cyclophosphamide, Fludarabine, and other medications for people whose adult T-cell leukemia/lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Cyclophosphamide (DRUG): Given IV | Fludarabine (DRUG): Given IV | Mogamulizumab (BIOLOGICAL): Given IV | Natural Killer Cell Therapy (BIOLOGICAL): Given via infusion | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies

Drugs / treatments
Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

NCT04848064

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing Cyclophosphamide, Fludarabine, and other medications for people whose adult T-cell leukemia/lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Cyclophosphamide (DRUG): Given IV | Fludarabine (DRUG): Given IV | Mogamulizumab (BIOLOGICAL): Given IV | Natural Killer Cell Therapy (BIOLOGICAL): Given via infusion | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies

Drugs / treatments: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 12 patients

Primary endpoint: Incidence of adverse events

Ages: 18 Years to —

Start date: 2022-05-06 | Est. completion: 2027-01-30

Locations

1 US sites · 1 total

Ohio

Contact

The Ohio State University Comprehensive Cancer Center | OSUCCCClinicaltrials@osumc.edu | 800-293-5066

Sponsor: John Reneau (OTHER)

Tags

ATLL · CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04848064

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.